Skip to main content

Table 1 Acalabrutinib (ACP-196) for hematological malignancies

From: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Agents Diseases Phase NCT
ACP-196
Dexamethasone
MM Phase 1 NCT02211014
ACP-196 ABC DLBCL Phase 1 NCT02112526
ACP-196
Rituximab (IV)
FL Phase 1 NCT02180711
ACP-196
Obinutuzumab
CLL, SLL, PLL Phase 1 NCT02296918
ACP-196
ACP-319
CLL Phase 1 NCT02157324
ACP-196
ACP-319
NHL, MM, B-All Phase 1/2 NCT02328014
ACP-196 WM Phase 1/2 NCT02180724
ACP-196 CLL, SLL, RS, PLL Phase 1/2 NCT02029443
ACP-196
Pembrolizumab
NHL, MM, HL, CLL, RS, WM, Myelofibrosis Phase 1/2 NCT02362035
ACP-196 CLL, SLL Phase 2 NCT02337829
ACP-196 MCL Phase 2 NCT02213926
ACP-196
Obinutuzumab
Chlorambucil
CLL Phase 3 NCT02475681
ACP-196
Ibrutinib
CLL Phase 3 NCT02477696
  1. NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, MCL mantle cell lymphoma, FL follicular lymphoma, ABC DLBCL activated B cell diffuse large B cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, WM Waldenstrom’s macroglobulinemia, RS Richter’s syndrome, PLL prolymphocytic leukemia